Actively Recruiting
Evaluating Safety and Dose Optimization of Surzetoclax Alone or With Other Antimyeloma Agents in Adults With RelapsedRefractory Multiple Myeloma
Led by AbbVie · Updated on 2026-10-27
325
Participants Needed
51
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and changes in disease activity of surzetoclax, an investigational oral drug, alone or combined with other treatments in adults with relapsed or refractory multiple myeloma MM, a disease where abnormal plasma cells grow in the bone marrow. This Phase 12 study is designed to find the best doses of surzetoclax in combination with other antimyeloma agents or alone, involving about 325 adult participants worldwide. The study includes multiple substudy phases to explore different drug combinations and dosing schedules for relapsedrefractory MM. Participants will receive surzetoclax with other drugs such as daratumumab given by injection, dexamethasone oral, pomalidomide oral, or etentamig intravenous infusion, depending on the substudy group. The study has dose escalation and optimization phases to determine the best doses of surzetoclax and other agents. Some participants will receive surzetoclax alone, while others receive it combined with other antimyeloma treatments. The total study duration is about 4.5 years. During the study, participants will attend regular visits at approved centers for medical assessments, blood tests, and monitoring of side effects. Researchers will track adverse events and measure disease activity changes. The main outcomes include dose-limiting toxicities and adverse events over up to 4.5 years. Secondary outcomes evaluate response rates, progression-free survival, duration of response, and overall survival. Participants will be closely monitored throughout the study period to assess treatment effects and safety.
CONDITIONS
Brief Title
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here